Hope for FOP: new drug aims to stop abnormal bone growth
Disease control
Terminated
This study tested two doses of an oral drug called fidrisertib (IPN60130) in children and adults with fibrodysplasia ossificans progressiva (FOP), a rare condition where bone forms in muscles and soft tissues, causing stiffness and disability. The goal was to see if the drug coul…
Phase: PHASE2 • Sponsor: Clementia Pharmaceuticals Inc. • Aim: Disease control
Last updated May 22, 2026 13:51 UTC